Research Article

Effects and Mechanisms of Electroacupuncture on Chronic Inflammatory Pain and Depression Comorbidity in Mice

Hung-Yu Huang,¹ Hsien-Yin Liao ^{2,3} and Yi-Wen Lin ^{4,5}

¹Department of Neurology, China Medical University Hospital, Taichung 40447, Taiwan

²College of Chinese Medicine, School of Post-Baccalaureate Chinese Medicine, China Medical University, Taichung 40402, Taiwan

³Department of Acupuncture, China Medical University Hospital, Taichung 40402, Taiwan

⁴College of Chinese Medicine, Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan

⁵Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan

Correspondence should be addressed to Hsien-Yin Liao; jamesliao1076@hotmail.com and Yi-Wen Lin; yiwenlin@mail.cmu.edu.tw

Received 4 November 2019; Revised 14 April 2020; Accepted 12 May 2020; Published 29 May 2020

Academic Editor: XiuMin Li

Copyright © 2020 Hung-Yu Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comorbidity of chronic pain and major depression disorder (MDD) are common diseases. However, the mechanisms of electroacupuncture (EA) and the responses of N-methyl-D-aspartate receptors in the brain remain unclear. Three injections of complete Freund's adjuvant (CFA) were administered to induce chronic inflammatory pain (CIP). EA was then performed once every other day from days 14 to 28. Behavior tests of chronic pain and depression were evaluated to make sure of the successful induction of comorbidity. We used Western blotting to analyze brain tissue from the prefrontal cortex (PFC), hippocampus, and hypothalamus for levels of phosphorylated N-methyl-D-aspartate receptor subunit 1 (pNR1), NR1, pNR2B, NR2B, and calcium/calmodulin-dependent protein kinase type II alpha isoform (pCaMKII α). The mechanical hyperalgesia, thermal hyperalgesia, and depression were observed in the CIP group. Furthermore, decreased levels of N-methyl-D-aspartate receptors (NMDARs) were also noted. Not Sham EA but EA reversed chronic pain and depression as well as the decreased levels of NMDA in the signaling pathway. The CFA injections successfully induced a significant comorbidity model. EA treated the comorbidity by upregulating the NMDA signaling pathway in the PFC, hippocampus, and hypothalamus. Our results indicated significant mechanisms of comorbidity of chronic pain and MDD and EA-analgesia that involves the regulation of the NMDAR signaling pathway. These findings may be relevant to the evaluation and treatment of comorbidity of chronic pain and MDD.

1. Introduction

Chronic pain and major depression disorder are common diseases among medical outpatients [1, 2]. In 2010, the economic burdens of MDD and pain in the United States were \$210.5 billion [3] and \$300 billion [4], respectively. Depression and pain had an estimated cooccurrence of up to 80% in 2015 [5]. Pain adversely affects the prognosis of depression and vice versa. One study indicated that patients with chronic pain had a significantly higher chance of developing depression (30%–54%) than the general population (5%–8%) [6]. Furthermore, patients with chronic pain from

physical conditions have longer depressive moods [7]. Similarly, another study showed that patients with MDD had a different prevalence and intensity of pain compared to healthy controls [8]. MDD and pain share biological pathways and neurotransmitters, which suggests that simultaneous treatment of both conditions may be effective [9].

Our previous animal model studies have illustrated the therapeutic effects of EA against inflammatory pain via neuronal and nonneuronal pathways [10, 11]. EA stimulated secretion of endogenous opioids through the anesthesia pain descending pathway in the central neural system [12].

Furthermore, several clinical studies have indicated that EA relieves chronic pain [13], such as knee osteoarthritis [14], low back pain [15–17], neck pain [18, 19], and shoulder pain [20]. According to previous studies of depressed rats, the antidepressive efficacy of EA treatment has been achieved through the mechanisms of enhancing 5-HT synthesis [21], raising protein levels of phosphorylated extracellular regulated protein kinases [22], and suppressing inflammatory cytokines [23] in the hippocampus. Moreover, EA potentially regulates the dopaminergic synapse signaling pathway by activating reward system [24].

However, among patients with major depression, there were around 10%–30% who did not improve under the use of antidepressants [25]. In addition, selective serotonin reuptake inhibitors (SSRIs) often take weeks to exert their full effects in treating MDD [26] and leave most patients with considerable residual symptoms. Therefore, researchers have endeavored to discover other possible mechanisms that can be used in the treatment of depression. In particular, two noteworthy studies have discovered the rapid antidepressant action of ketamine [27, 28]. The level of beta form of calcium/calmodulin-dependent protein kinase type II (β CaMKII) was significantly upregulated in the lateral habenula of depressive animal models. The β CaMKII was one of the downstream factors controlled by NMDAR. By blocking the NMDAR-dependent burst firing of lateral habenula, Ketamine could reverse the suppression of reward center and caused rapid antidepressant effects.

On the basis of the aforementioned findings, we assumed that EA ameliorates pain and MDD. To further uncover the mechanisms linking EA, comorbidity, and NMDARs, we established a chronic pain and depression comorbidity model and used EA as the intervention. This study improves our understanding of how acupuncture treats comorbidities, using findings obtained through behavioral observation and the measurement of biomarkers in different brain cores.

2. Methods

2.1. Experimental Animals and Ethical Considerations. All animals were treated in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals, and the study protocol was approved by the ethics committee of the China Medical University, Taichung, Taiwan (permit no. 2017-374). C57/B6 male mice weighing approximately 22–25 g and aged 8–12 weeks were purchased from the BioLASCO Animal Center, Taipei, Taiwan. Animals were housed in plexiglass cages in a temperature-controlled room ($25 \pm 2^\circ\text{C}$) with a relative humidity of $60 \pm 5\%$ and were fed a diet of standard rat chow and water ad libitum.

2.2. Chronic Inflammatory Pain and Depression Model. There were four groups in the present study. A total of eight mice in each group were determined as the minimum number necessary to carry out the experiments. All experiments were performed at laboratory during daylight hours. C57/B6 mice were randomly (simple random sampling) divided into four groups and then anesthetized with

1% isoflurane for CFA injections and EA treatment. Then mice were injected with $20\ \mu\text{L}$ saline (pH 7.4, buffered with 20 mM HEPES) or CFA $20\ \mu\text{L}$ (complete Freund's adjuvant; 0.5 mg/ml heat-killed *M. tuberculosis* (Sigma, St. Louis, MO)) as previous study [29] in the plantar surface of the hind paw. CFA was used to induce intraplantar chronic inflammation. The $20\ \mu\text{L}$ of saline and $20\ \mu\text{L}$ of CFA were administered thrice: at baseline, at day 7, and at day 14. The four groups and their treatments were as follows: (1) control group: anesthesia with normal saline injection; (2) chronic inflammatory pain (CIP) group: anesthesia with CFA injections to induce chronic inflammatory pain and depression; (3) EA group: anesthesia with CFA injections and EA manipulation; and (4) sham EA group: anesthesia with CFA injections and sham EA to determine the roles played by acupoints.

2.3. Electroacupuncture and Sham Electroacupuncture. EA treatment was applied by stainless steel acupuncture needles (1.5" inches, 30G, YU KUANG, Taiwan) that were inserted into the muscle layer at a depth of 3–4 mm at the ST36 acupoint. Several articles indicated the analgesic effect and pathway of EA on the ST36 acupoint [10, 11]. Electrical square pulses generated by the stimulator were delivered for 15 min—at 2 Hz, with $100\ \mu\text{s}$ between each pulse and a 1 mA amplitude. EA was carried out in the morning (9:00–10:00 am), twice a day, from day 14 to day 28. The same treatment was administered to a nonacupoint (3 mm away from ST36 but not GB34 [30, 31]) in the sham control group. By comparing the two groups, we aimed to demonstrate the specificity of acupoints under EA treatment. According to a review article [32], researchers proved that, through the different stimulation site with electroacupuncture or manual acupuncture, different afferent fibers such as thick myelinated A α and A β , thin myelinated A δ , and thinner unmyelinated C fibers would be stimulated with different treatment effects. We did not want to explore the different effects between EA and manual acupuncture in this study, so we did not establish a group with manual acupuncture on ST36.

2.4. Behavioral Tests for Chronic Pain: von Frey Test and Hargreaves Test. Beginning the first day after intraplantar CFA injection, mechanical sensitivities were tested every other day for 28 days. All experiments were performed at room temperature (approximately 25°C), and the stimuli were applied only when the animals were calm but not sleeping or grooming. Mechanical sensitivity was measured by testing the force of response to the stimulus from three applications of electronic von Frey filaments (North Coast Medical, Gilroy, CA, USA). The average thermal pain from three applications was measured using a Hargreaves test IITC analgesimeter (IITC Life Sciences, Woodland Hills, CA, USA).

2.5. Behavioral Tests of Depression: Forced Swimming Test and Open Field Test. EthoVision XT 8.5 (Noldus Information Technology, Wageningen, Netherlands) video-tracking

software was used to automatically score anxiety-like behaviors in a forced swimming test (FST) and open field test (OFT) on day 28. The FST apparatus was a plastic cylinder (47 cm height, 38 cm inside diameter) containing 38 cm of water at $25 \pm 1^\circ\text{C}$. The water level was deep enough (18 cm) so the tail of the mouse never touched the bottom. The water was replaced between each test. The mice were exposed to forced swimming and their immobile behavior is measured and considered a “depression-like” phenotype. The FST comprised two phases. In the initial 15 min habituation session, which, as a training procedure, was excluded from the data analysis, the mice were individually forced to swim in a plastic cylinder. If an animal appeared to be in serious distress like tiredness or floating disability, the animal would be removed from the water and excluded from the experiment. After a period of vigorous swimming, all mice economized their movements to only those necessary to maintain their head above the water, with no other displacement. The 5 min test sessions began 24 hours later. The duration of immobilization was measured. After the test, the mice were removed and dried with a towel before being returned to their home cages. Increased immobility in the forced swimming test was indicative of depression-like behavior.

The OFT box was composed of black acrylic plastic that formed a 30×30 cm square with a wall height of 15 cm. The box was divided into nine equal squares. Each mouse was placed in the center zone of an open field at the beginning and allowed to explore the maze for 15 min. The distance of crossing the central zone, the duration in the center area, and the total movement in the open field were analyzed. A low frequency of crossing the central zone or a short duration of time spent within the central zone was considered a validation of depression.

2.6. Tissue Sampling and Western Blot. The mice were sacrificed using CO_2 to minimize their suffering. The prefrontal cortex (PFC), hippocampus, and hypothalamus were harvested on day 28 and then immediately excised to extract proteins. Total proteins were prepared in lysis buffer containing 50 mM Tris-HCl pH 7.4, 250 mM NaCl, 1% NP-40, 5 mM EDTA, 50 mM NaF, 1 mM Na_3VO_4 , 0.02% NaN_3 , and 1x protease inhibitor cocktail (AMRESCO). The extracted proteins (30 μg per sample assessed through BCA protein assay) were subjected to 8% SDS-Tris glycine gel electrophoresis and transferred to a PVDF membrane. The membrane was blocked with 5% nonfat milk in TBS-T buffer (10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween 20), incubated with first antibody (anti-pNR1, anti-NR1, anti-pNR2B, anti-NR2B, and anti-pCaMKII α) in TBS-T with 1% bovine serum albumin, and incubated for 1 hour at room temperature. Peroxidase-conjugated anti-rabbit antibody (1 : 5000) was used as a secondary antibody. The bands were visualized by an enhanced chemiluminescence substrate kit (PIERCE) with LAS-3000 Fujifilm (Fuji Photo Film Co. Ltd.). Wherever applicable, the image intensities of specific bands were quantified with NIH ImageJ software (Bethesda, MD, USA).

2.7. Immunofluorescence Staining. A total of 4 subjects, from the Con, CIP, EA, and sham EA groups, were anesthetized using 1% isoflurane through inhalation and intracardially perfused with saline followed by 4% paraformaldehyde. The brain was immediately dissected and postfixed with 4% paraformaldehyde at 4°C overnight. The postfixed tissues were placed overnight in 30% sucrose for cryoprotection at 4°C . The brain was embedded in OCT and instantaneously frozen using liquid nitrogen prior to storage at -80°C . The coronal sections containing the medial PFC (mPFC), hippocampal CA1, and hypothalamus were cut into 16 μm thick slices through cryosectioning. The samples were incubated with blocking solution, which consisted of 3% bovine serum albumin (BSA), 0.1% Triton X-100, and 0.02% sodium azide, for 2 h at room temperature. Following blocking, the brain samples were incubated overnight with the primary antibodies, which was prepared in BSA solution at 4°C overnight. The secondary antibodies, peroxidase-conjugated anti-rabbit antibody, (1 : 5000) were used for incubation at room temperature for 2 h prior to fixation with cover slips for immunofluorescence visualization. Using a microscope (Olympus, BX-51, Japan), we searched for the presence of immune-positive neurons among the mPFC, hippocampal CA1, and hypothalamus slices.

2.8. Statistical Analysis. The experimental results for each group are expressed as means $\pm$ standard deviation. A paired *t*-test and one-way ANOVA were performed for intragroup and intergroup statistical analyses. The one-way ANOVA was followed by Tukey's post hoc test. Statistical significance was indicated if $p < 0.05$. SPSS for Windows (version 21.0, SPSS, Chicago, IL, USA) was used for all statistical analyses.

3. Results

3.1. Electroacupuncture Significantly Attenuated Mechanical and Thermal Hyperalgesia in the Chronic Pain and Depression Comorbidity Model. As shown in Figure 1(a), mechanical sensitivity did not differ among the four groups under basal conditions. A significant lower pain threshold, namely, mechanical hyperalgesia, was observed in the CIP group and sham EA group on days 14 and 28 when compared with the control group (Figure 1(a), $p < 0.05$, $n = 8$). However, EA significantly reduced mechanical hyperalgesia (Figure 1(a), $p < 0.05$, $n = 8$). Figure 1(b) showed similar results. There was no significant difference of withdrawal latencies among all groups prior to CFA injections. However, on days 14 and 28, the withdrawal latencies in the CIP group and the sham EA group (Figure 1(b), $p < 0.05$, $n = 8$) were shorter than that among the control group (Figure 1(b), $p < 0.05$, $n = 8$). Interestingly, EA also significantly reduced thermal hyperalgesia (Figure 1(b), $p < 0.05$, $n = 8$).

3.2. Electroacupuncture Significantly Attenuated Depressive Behavior in the Chronic Pain and Depression Comorbidity Model. On day 28, the results of the OFTs were presented in Figures 1(c) and 1(d). Mice among the four groups

FIGURE 1: EA significantly attenuated mechanical, thermal hyperalgesia, and depression induced by CFA. (a) Changes in the withdraw threshold of mice in the von Frey test. (b) Changes in the withdraw latency of mice in the radial heat test. Figures 1(c) and 1(d) present the day 28 OFT results. After accepting EA, the time mice stayed in the center area longer. (c) The distance mice stayed in the central area. (d) The percentage of time mice spent in the center area. Day 28 FST results are presented in Figures 1(e) and 1(f). EA reduced the immobility of mice. (e) Duration of immobility spent in the FST. (f) Frequency of immobility counted in the FST. * $p < 0.05$ for CIP versus control. # $p < 0.05$ for EA versus CIP.

performed similarly in the total distance of the OFT. The distance in the central area was significantly shorter in the CIP group and sham EA group in comparison to that of the control group (Figure 1(c), $p < 0.05$, $n = 8$). EA significantly increased the distance in the central area (Figure 1(c),

$p < 0.05$, $n = 8$). The percentage of time spent in the center of the OFT, depicted in Figure 1(d), showed similar result as Figure 1(c). The results of FST on day 28 were shown as Figures 1(e) and 1(f). Among CIP group and sham EA group, the percentage of immobile time and the frequency of

FIGURE 2: Expression levels of pCaMKII α in the mPFC, hippocampal CA1, and hypothalamus for all four groups. (a) Representative immunofluorescence staining of pCaMKII α (green) in the mice mPFC; (b) representative immunofluorescence staining of pCaMKII α (green) in the mice hippocampal CA1; (c) representative immunofluorescence staining of pCaMKII α (green) in the mice hypothalamus. Arrows indicate immunopositive neurons.

counted immobility were higher than control group. EA reduced the immobility of mice.

3.3. Electroacupuncture Upregulated Reduced NMDARs in CIP Mouse Brain. To test the effect of CIP on NMDA levels, we investigated the effect of EA as exerted through the NMDA signaling pathway in the mice prefrontal cortex (PFC) region. Expression of pNR1 was significantly decreased in the PFC of CIP mice (Figure 3(a), $p < 0.05$, $n = 6$), and the phenomenon was significantly reversed by EA treatment (Figure 3(a), $p < 0.05$, $n = 6$). In addition, pNR1 expression was significantly reduced in the sham EA group (Figure 3(a), $p < 0.05$, $n = 6$). Similar results were also obtained in NR1 protein levels (Figure 3(b), $n = 6$). Furthermore, pNR2B were significantly decreased in the CIP group compared to the control group (Figure 3(c), $p < 0.05$, $n = 6$). In contrast, this decrease was significantly reversed by EA treatment (Figure 3(c), $p < 0.05$, $n = 6$). Sham EA operation did not have effect on decreased pNR2B protein levels (Figure 3(c), $p < 0.05$, $n = 6$). Notably, a similar tendency was observed in the NR2B protein expression (Figure 3(d), $n = 6$). Moving along the signaling cascade, we next test the protein levels of pCaMKII α . Accordingly, we indicated a significantly reduced expression of pCaMKII α in CIP group (Figure 3(e), $p < 0.05$, $n = 6$). The pCaMKII α protein levels were significantly increased in the EA group (Figure 3(e), $p < 0.05$, $n = 6$) but not in the sham EA group (Figure 3(e), $p < 0.05$, $n = 6$). The aforementioned results indicate that the NMDA signaling pathways are commonly associated with the chronic pain and depression comorbidity mice.

We next examined the NMDA signal pathways in the mice hippocampus. It was ascertained that CIP induced a significant reduction of pNR1 in the CIP mice (Figure 4(a), $p < 0.05$, $n = 6$). EA has a significant increase in the pNR1 levels (Figure 4(a), $p < 0.05$, $n = 6$), which was not observed in the sham EA group (Figure 4(a), $p < 0.05$, $n = 6$). Similar tendency was obtained in the NR1 protein levels (Figure 4(b), $n = 6$). Again, the decrease of pNR2B and NR2B suggested a similar tendency as observed in mice hippocampus, displaying decreased protein levels in CIP mice (Figure 4(c) and 4(d), $p < 0.05$, $n = 6$). In addition, the phenomena were rescued by EA treatment but not sham EA group (Figure 4(c) and 4(d), $p < 0.05$, $n = 6$). The pCaMKII α has lowered expressed in the CIP group (Figure 4(e), $p < 0.05$, $n = 6$) and then rescued by EA treatment but not sham EA group (Figure 4(e), $p < 0.05$, $n = 6$). Similar tendency was also observed in the mice hypothalamus (Figure 5, $n = 6$).

Furthermore, we utilized the immunofluorescence technique to identify the pCaMKII α protein expression in the mPFC, hippocampal CA1, and hypothalamus that is crucial for chronic pain and depression. The images of the mPFC area displayed significantly decreased pCaMKII α in the CIP and sham EA groups. These protein levels significantly increased in the EA group (Figure 2(a)). Additionally, the proteins pCaMKII α displayed similar tendencies in hippocampal CA1 and hypothalamus areas (Figures 2(b) and 2(c)).

4. Discussion

Mechanical and thermal hyperalgesia confirmed that CFA injections successfully evoked inflammatory pain. On day

FIGURE 3: Protein levels of (a) pNR1 (b) NR1, (c) pNR2B, (d) NR2B, and (e) pCaMKIIα, measured through Western blotting in mice mPFC. * $p < 0.05$ versus control. The Western blot bands at the top indicate the cropped target protein. The lower bands indicate the cropped internal controls (β -actin or α -tubulin).

28, the decreased distance traversed in the center square during the OFT and increased immobility during the FST demonstrated our successful induction of depression. As indicated by the difference between the CIP and EA groups, EA from days 14 to 28 reduced pain and depression. We also demonstrated the specificity of acupoint ST36 for the amelioration of comorbidity, by comparing data from the EA group and sham EA group.

Depression and pain affect each other. They also share neural circuitry and molecular signaling pathways; however, the same neuromolecular mechanisms sometimes lead to contrary effects in the different brain cores [9, 33]. For example, high-frequency repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal

cortex is an FDA approved therapeutic intervention for drug-resistant major depression [34]. The increasing levels of glutamate were found among responders accepting rTMS [35]. By contrast, glutamatergic excitatory neurotransmission in the lateral habenula causes depression [36, 37] by inhibiting the reward center involving regions such as the dopaminergic ventral tegmental area and serotonergic dorsal raphe nucleus [27, 28].

A study reported decreased expression of the NMDAR subunits NR2A (by -54%) and NR2B (by -48%) in the anterior PFC of people with depression [38]. Magnetic resonance spectroscopy also revealed lower glutamate/glutamine levels in the PFC [39]. Moreover, a study noted that animals with depression had (1) reduced levels of NMDAR

FIGURE 4: Protein levels of (a) pNR1 (b) NR1, (c) pNR2B, (d) NR2B, and (e) pCaMKII α , measured using Western blotting, in mice hippocampus. * $p < 0.05$ versus control. Western blot bands at the top indicate the cropped target protein. Lower bands indicate the cropped internal controls (β -actin or α -tubulin).

subunits NR1 and NR2A in the hippocampus and (2) reduced NR1 in the PFC [40]. In particular, hippocampal volume reduction is the most replicated finding in neuroimaging studies of MDD [41]. Hypothalamic-pituitary-adrenal (HPA) axis hyperactivity and hypoactivity have been reported in depression, but using HPA activity as a depression biomarker is challenging [42]. Before the development of chronic pain, the HPA axis may become hyperactive; however, long-term hyperactivity may result in an exhausted stress system and ultimately a hypoactive HPA axis [43]. Therefore, we (1) chose the NMDAR subtype of the excitatory glutamate receptor family as the main biomarker

to assess the antidepressive effect of EA and (2) chose the PFC, hippocampus, and hypothalamus as the main cerebral cores to study.

In the CIP and sham EA groups, the levels of pNR1, NR1, pNR2B, NR2B, and pCaMKII α decreased by day 28 in the PFC, hippocampus, and hypothalamus after three injections of CFA (Figures 3–5). The level of NMDARs among CIP and sham EA groups was lower than that of control group, with EA reversing the decreasing trends. In the same brain cores presented in Figure 2, our immunostaining data indicated that the protein levels pCaMKII α , which reflected potential downstream signaling mechanisms controlled by NMDA

FIGURE 5: Protein levels of (a) pNR1 (b) NR1, (c) pNR2B, (d) NR2B, and (e) pCaMKII α , measured using Western blotting in mice hypothalamus. * $p < 0.05$ versus control. Western blot bands at the top indicate the cropped target protein. Lower bands indicate the cropped internal controls (β -actin or α -tubulin).

phosphorylation, were lower among CIP and Sham EA groups and reversed by EA. The antidepressive effect of EA could be partly disclosed by the present study, which showed EA reversing the decreasing glutamatergic excitatory neurotransmitters such as NMDARs and pCaMKII α . Our study has some limitations. First, we did not study cerebral areas such as the amygdala, cingulate cortex, and ventral tegmental area that are involved in comorbid chronic pain and depression. Some neurotransmitters, such as

norepinephrine and dopamine, may also be affected by the comorbidity. Other antagonists of neurotransmitters should be investigated to understand EA's further mechanisms.

The current study provides evidence into how NMDA and related molecules participates in chronic pain and depression behaviors. EA significantly reversed decreases in NMDA and related molecules in the mouse PFC, hippocampus, and hypothalamus, suggesting involvement at multiple levels and emphasizing the possibility of leveraging

them in functional therapeutic interventions. Clinical trials should be performed to clarify the subsequent application of TRPV1 as a treatment target for chronic pain and depression comorbidity.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no potential conflicts of interest from any commercial or financial relationships.

Authors' Contributions

Hung-Yu Huang and Hsien-Yin Liao conceived the study design, conducted the experiments, and collected and analyzed the data. Hsien-Yin Liao and Yi-Wen Lin wrote the manuscript. All the authors have reviewed the manuscript and agreed to its submission.

Acknowledgments

This study was financially supported by the China Medical University Hospital, under nos. DMR-107-010 and CMU108-MF-28, MOST 108-2320-B-039 -028 -MY3, and "Chinese Medicine Research Center, China Medical University" from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.

References

- [1] K. Kroenke, "Patients presenting with somatic complaints: epidemiology, psychiatric co-morbidity and management," *International Journal of Methods in Psychiatric Research*, vol. 12, no. 1, pp. 34–43, 2003.
- [2] R. L. Spitzer, K. Kroenke, M. Linzer et al., "Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study," *JAMA: The Journal of the American Medical Association*, vol. 274, no. 19, pp. 1511–1517, 1995.
- [3] P. E. Greenberg, A.-A. Fournier, T. Sisitsky, C. T. Pike, and R. C. Kessler, "The economic burden of adults with major depressive disorder in the United States (2005 and 2010)," *The Journal of Clinical Psychiatry*, vol. 76, no. 2, pp. 155–162, 2015.
- [4] D. J. R. P. Gaskin, *The Economic Costs of Pain in the United States*, Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education, Washington, DC, USA, 2011, <https://www.ncbi.nlm.nih.gov/books/NBK92521/>.
- [5] M. Fitzgibbon, D. P. Finn, and M. Roche, "High times for painful blues: the endocannabinoid system in pain-depression comorbidity," *International Journal of Neuropsychopharmacology*, vol. 19, no. 3, Article ID pyv095, 2015.
- [6] B. T. Baune, R. N. Caniato, M. A. Garcia-Alcaraz, and K. Berger, "Combined effects of major depression, pain and somatic disorders on general functioning in the general adult population," *Pain*, vol. 138, no. 2, pp. 310–317, 2008.
- [7] M. M. Ohayon and A. F. Schatzberg, "Using chronic pain to predict depressive morbidity in the general population," *Archives of General Psychiatry*, vol. 60, no. 1, pp. 39–47, 2003.
- [8] T. Kishi, Y. Matsuda, T. Mukai et al., "A cross-sectional survey to investigate the prevalence of pain in Japanese patients with major depressive disorder and schizophrenia," *Comprehensive Psychiatry*, vol. 59, pp. 91–97, 2015.
- [9] A. K. Walker, A. Kavelaars, C. J. Heijnen, and R. Dantzer, "Neuroinflammation and comorbidity of pain and depression," *Pharmacological Reviews*, vol. 66, no. 1, pp. 80–101, 2014.
- [10] H. Y. Liao, C. L. Hsieh, C. P. Huang, and Y. W. Lin, "Electroacupuncture attenuates CFA-induced inflammatory pain by suppressing Nav1.8 through S100B, TRPV1, opioid, and adenosine pathways in mice," *Scientific Reports*, vol. 7, Article ID 42531, 2017.
- [11] H.-Y. Liao, C.-L. Hsieh, C.-P. Huang, and Y.-W. Lin, "Electroacupuncture attenuates induction of inflammatory pain by regulating opioid and adenosine pathways in mice," *Scientific Reports*, vol. 7, Article ID 15679, 2017.
- [12] R. Zhang, L. Lao, K. Ren, and B. M. Berman, "Mechanisms of acupuncture-electroacupuncture on persistent pain," *Anesthesiology*, vol. 120, no. 2, pp. 482–503, 2014.
- [13] H. MacPherson, A. C. Maschino, G. Lewith, N. E. Foster, C. M. Witt, and A. J. Vickers, "Characteristics of acupuncture treatment associated with outcome: an individual patient meta-analysis of 17,922 patients with chronic pain in randomised controlled trials," *PLoS One*, vol. 8, Article ID e77438, 2013.
- [14] C. I. Mavrommatis, E. Argyra, A. Vadalouka, and D. G. Vasilakos, "Acupuncture as an adjunctive therapy to pharmacological treatment in patients with chronic pain due to osteoarthritis of the knee: a 3-armed, randomized, placebo-controlled trial," *Pain*, vol. 153, no. 8, pp. 1720–1726, 2012.
- [15] E. Leibing, U. Leonhardt, G. Köster et al., "Acupuncture treatment of chronic low-back pain - a randomized, blinded, placebo-controlled trial with 9-month follow-up," *Pain*, vol. 96, no. 1, pp. 189–196, 2002.
- [16] A. F. Molsberger, J. Mau, D. B. Pawelec, and J. Winkler, "Does acupuncture improve the orthopedic management of chronic low back pain - a randomized, blinded, controlled trial with 3 months follow up," *Pain*, vol. 99, no. 3, pp. 579–587, 2002.
- [17] B. M. Berman, H. M. Langevin, C. M. Witt, and R. Dubner, "Acupuncture for chronic low back pain," *New England Journal of Medicine*, vol. 363, no. 5, pp. 454–461, 2010.
- [18] C. M. Witt, S. Jena, B. Brinkhaus, B. Liecker, K. Wegscheider, and S. N. Willich, "Acupuncture for patients with chronic neck pain," *Pain*, vol. 125, no. 1, pp. 98–106, 2006.
- [19] J. Vas, E. Perea-Milla, C. Méndez et al., "Efficacy and safety of acupuncture for chronic uncomplicated neck pain: a randomised controlled study," *Pain*, vol. 126, no. 1, pp. 245–255, 2006.
- [20] A. F. Molsberger, T. Schneider, H. Gotthardt, and A. Drabik, "German Randomized Acupuncture Trial for chronic shoulder pain (GRASP) - a pragmatic, controlled, patient-blinded, multi-centre trial in an outpatient care environment," *Pain*, vol. 151, no. 1, pp. 146–154, 2010.
- [21] D. Duan, Y. Tu, X. Yang, and P. Liu, "Electroacupuncture restores 5-HT system deficit in chronic mild stress-induced depressed rats," *Evidence-based Complementary and Alternative Medicine*, vol. 2016, Article ID 7950635, 9 pages, 2016.
- [22] J. Xu, Y. She, N. Su, R. Zhang, L. Lao, and S. Xu, "Effects of electroacupuncture on chronic unpredictable mild stress rats depression-like behavior and expression of p-ERK/ERK and

- p-P38/P38," *Evidence-Based Complementary and Alternative Medicine*, vol. 2015, Article ID 650729, 8 pages, 2015.
- [23] N. Yue, B. Li, L. Yang et al., "Electro-acupuncture alleviates chronic unpredictable stress-induced depressive- and anxiety-like behavior and hippocampal neuroinflammation in rat model of depression," *Frontiers in Molecular Neuroscience*, vol. 11, p. 149, 2018.
 - [24] X. Yang, Z. Guo, J. Lu et al., "The role of MAPK and dopaminergic synapse signaling pathways in antidepressant effect of electroacupuncture pretreatment in chronic restraint stress rats," *Evidence-Based Complementary and Alternative Medicine*, vol. 2017, Article ID 2357653, 9 pages, 2017.
 - [25] K. S. Al-Harbi, "Treatment-resistant depression: therapeutic trends, challenges, and future directions," *Patient Preference and Adherence*, vol. 6, pp. 369–388, 2012.
 - [26] R. Machado-Vieira, J. Baumann, C. Wheeler-Castillo et al., "The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments," *Pharmaceuticals*, vol. 3, no. 1, pp. 19–41, 2010.
 - [27] Y. Cui, Y. Yang, Z. Ni et al., "Astroglial Kir4.1 in the lateral habenula drives neuronal bursts in depression," *Nature*, vol. 554, no. 7692, pp. 323–327, 2018.
 - [28] Y. Yang, Y. Cui, K. Sang et al., "Ketamine blocks bursting in the lateral habenula to rapidly relieve depression," *Nature*, vol. 554, no. 7692, pp. 317–322, 2018.
 - [29] M. Narita, C. Kaneko, K. Miyoshi et al., "Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala," *Neuropsychopharmacology*, vol. 31, no. 4, pp. 739–750, 2006.
 - [30] S. Lim, "WHO standard acupuncture point locations," *Evidence-Based Complementary and Alternative Medicine*, vol. 7, no. 2, pp. 167–168, 2010.
 - [31] Y.-T. Liu, Y.-W. Shao, C.-T. Yen, and F.-Z. Shaw, "Acid-induced hyperalgesia and anxio-depressive comorbidity in rats," *Physiology & Behavior*, vol. 131, pp. 105–110, 2014.
 - [32] F. Kagitani, S. Uchida, and H. Hotta, "Afferent nerve fibers and acupuncture," *Autonomic Neuroscience*, vol. 157, no. 1–2, pp. 2–8, 2010.
 - [33] L. Doan, T. Manders, and J. Wang, "Neuroplasticity underlying the comorbidity of pain and depression," *Neural Plasticity*, vol. 2015, pp. 504691–16, 2015.
 - [34] M. J. Lan, B. T. Chhetry, C. Liston, J. J. Mann, and M. Dubin, "Transcranial magnetic stimulation of left dorsolateral prefrontal cortex induces brain morphological changes in regions associated with a treatment resistant major depressive episode: an exploratory analysis," *Brain Stimulation*, vol. 9, no. 4, pp. 577–583, 2016.
 - [35] A. Luborzewski, F. Schubert, F. Seifert et al., "Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression," *Journal of Psychiatric Research*, vol. 41, no. 7, pp. 606–615, 2007.
 - [36] W. Cui, H. Mizukami, M. Yanagisawa et al., "Glial dysfunction in the mouse habenula causes depressive-like behaviors and sleep disturbance," *The Journal of Neuroscience*, vol. 34, no. 49, pp. 16273–16285, 2014.
 - [37] S. Kang, J. Li, A. Bekker, and J.-H. Ye, "Rescue of glutamate transport in the lateral habenula alleviates depression- and anxiety-like behaviors in ethanol-withdrawn rats," *Neuropharmacology*, vol. 129, pp. 47–56, 2018.
 - [38] A. M. Feyissa, A. Chandran, C. A. Stockmeier, and B. Karlewicz, "Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression," *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 33, no. 1, pp. 70–75, 2009.
 - [39] M. J. Niciu, D. F. Ionescu, E. M. Richards, and C. A. Zarate Jr, "Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder," *Journal of Neural Transmission*, vol. 121, no. 8, pp. 907–924, 2014.
 - [40] H. Sun, L. Guan, Z. Zhu, and H. Li, "Reduced levels of NR1 and NR2A with depression-like behavior in different brain regions in prenatally stressed juvenile offspring," *PLoS One*, vol. 8, Article ID e81775, 2013.
 - [41] D. W. Roddy, C. Farrell, K. Doolin et al., "The Hippocampus in depression: more than the sum of its parts? Advanced hippocampal substructure segmentation in depression," *Biological Psychiatry*, vol. 85, no. 6, pp. 487–497, 2018.
 - [42] N. Bowens, W. Heydendael, S. Bhatnagar, and L. Jacobson, "Lack of elevations in glucocorticoids correlates with dysphoria-like behavior after repeated social defeat," *Physiology & Behavior*, vol. 105, no. 4, pp. 958–965, 2012.
 - [43] E. Generaal, N. Vogelzangs, G. J. Macfarlane et al., "Reduced hypothalamic-pituitary-adrenal axis activity in chronic multi-site musculoskeletal pain: partly masked by depressive and anxiety disorders," *BMC Musculoskeletal Disorders*, vol. 15, p. 227, 2014.